SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
Alleles
Animals
Cell Cycle
Cell Cycle Checkpoints
Cell Line, Tumor
Cytarabine
/ pharmacology
DNA Damage
Drug Resistance, Neoplasm
/ genetics
Epigenesis, Genetic
Female
Gene Expression Regulation, Leukemic
Heterozygote
Histone-Lysine N-Methyltransferase
/ genetics
Humans
Leukemia, Myeloid, Acute
/ genetics
Male
Mice
Mice, Transgenic
Mutation
Myeloid-Lymphoid Leukemia Protein
/ genetics
Neoplasm Recurrence, Local
Nuclear Proteins
/ genetics
Phenotype
Signal Transduction
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
29
05
2018
accepted:
13
03
2019
revised:
27
02
2019
pubmed:
11
4
2019
medline:
2
6
2020
entrez:
11
4
2019
Statut:
ppublish
Résumé
SETD2, an epigenetic tumor suppressor, is frequently mutated in MLL-rearranged (MLLr) leukemia and relapsed acute leukemia (AL). To clarify the impact of SETD2 mutations on chemotherapy sensitivity in MLLr leukemia, two loss-of-function (LOF) Setd2-mutant alleles (Setd2
Identifiants
pubmed: 30967619
doi: 10.1038/s41375-019-0456-2
pii: 10.1038/s41375-019-0456-2
pmc: PMC6785365
mid: NIHMS1031993
doi:
Substances chimiques
KMT2A protein, human
0
MLLT3 protein, human
0
Mllt3 protein, mouse
0
Nuclear Proteins
0
Cytarabine
04079A1RDZ
Myeloid-Lymphoid Leukemia Protein
149025-06-9
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
Kmt2a protein, mouse
EC 2.1.1.43
SETD2 protein, human
EC 2.1.1.43
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2585-2598Subventions
Organisme : NCI NIH HHS
ID : R21 CA187276
Pays : United States
Références
Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–907.
pubmed: 17126723
doi: 10.1016/S0140-6736(06)69780-8
Short NJ, Ravandi F. Acute myeloid leukemia: past, present, and prospects for the future. Clin Lymphoma Myeloma Leuk. 2016;16(Suppl):S25–9.
pubmed: 27521321
doi: 10.1016/j.clml.2016.02.007
Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.
pubmed: 27151159
pmcid: 4858828
doi: 10.1186/s12916-016-0623-5
Nagler E, Xavier MF, Frey N. Updates in immunotherapy for acute myeloid leukemia. Transl Cancer Res. 2017;6:86–92.
doi: 10.21037/tcr.2017.02.14
Hourigan CS. Editorial: targets for immunotherapy in acute leukemia. Curr Drug Targets. 2017;18:256.
pubmed: 28264642
pmcid: 6354584
doi: 10.2174/1389450117999151116144835
Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566–81.
pubmed: 27550819
pmcid: 5543811
doi: 10.1038/nrc.2016.97
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–26.
pubmed: 24060863
doi: 10.1038/nrc3599
Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y, et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet. 2014;46:287–93.
pubmed: 24509477
pmcid: 4440318
doi: 10.1038/ng.2894
Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014;5:3469.
pubmed: 24662245
doi: 10.1038/ncomms4469
Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, et al. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. 2017;130:2631–41.
pubmed: 29018079
pmcid: 5731084
doi: 10.1182/blood-2017-03-775569
Xiao H, Wang LM, Luo Y, Lai X, Li C, Shi J, et al. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. Oncotarget. 2016;7:2696–708.
pubmed: 26527318
doi: 10.18632/oncotarget.6259
Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, et al. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood. 2012;120:1118–29.
pubmed: 22740449
pmcid: 3412332
doi: 10.1182/blood-2012-02-412379
Li M, Phatnani HP, Guan Z, Sage H, Greenleaf AL, Zhou P. Solution structure of the Set2-Rpb1 interacting domain of human Set2 and its interaction with the hyperphosphorylated C-terminal domain of Rpb1. Proc Natl Acad Sci USA. 2005;102:17636–41.
pubmed: 16314571
doi: 10.1073/pnas.0506350102
pmcid: 1308900
Hu M, Sun XJ, Zhang YL, Kuang Y, Hu CQ, Wu WL, et al. Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling. Proc Natl Acad Sci USA. 2010;107:2956–61.
pubmed: 20133625
doi: 10.1073/pnas.0915033107
pmcid: 2840328
Krogan NJ, Kim M, Tong A, Golshani A, Cagney G, Canadien V, et al. Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II. Mol Cell Biol. 2003;23:4207–18.
pubmed: 12773564
pmcid: 427527
doi: 10.1128/MCB.23.12.4207-4218.2003
Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, et al. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia. 2016;30:2179–86.
pubmed: 27282254
pmcid: 5023049
doi: 10.1038/leu.2016.134
Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J, et al. The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J. 1999;18:3564–74.
pubmed: 10393173
pmcid: 1171435
doi: 10.1093/emboj/18.13.3564
Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010;24:1785–8.
pubmed: 20686503
pmcid: 5439963
doi: 10.1038/leu.2010.158
Bu J, Chen A, Yan X, He F, Dong Y, Zhou Y, et al. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia. Leukemia. 2018;32:890–9.
pubmed: 29249820
doi: 10.1038/leu.2017.339
Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–9.
pubmed: 12781359
doi: 10.1016/S1535-6108(03)00110-7
Schnerch D, Yalcintepe J, Schmidts A, Becker H, Follo M, Engelhardt M, et al. Cell cycle control in acute myeloid leukemia. Am J Cancer Res. 2012;2:508–28.
pubmed: 22957304
pmcid: 3433102
Andreassen PR, Martineau SN, Margolis RL. Chemical induction of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state. Mutat Res. 1996;372:181–94.
pubmed: 9015137
doi: 10.1016/S0027-5107(96)00138-8
Andreassen PR, Lacroix FB, Lohez OD, Margolis RL. Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells. Cancer Res. 2001;61:7660–8.
pubmed: 11606409
Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8:2992–3000.
pubmed: 19887545
doi: 10.1158/1535-7163.MCT-09-0463
Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011;10:591–602.
pubmed: 21321066
doi: 10.1158/1535-7163.MCT-10-0928
Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia. 2012;26:1266–76.
pubmed: 22289989
pmcid: 3678731
doi: 10.1038/leu.2011.392
Li FX, Zhu JW, Hogan CJ, DeGregori J. Defective gene expression, S phase progression, and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol Cell Biol. 2003;23:3607–22.
pubmed: 12724419
pmcid: 164755
doi: 10.1128/MCB.23.10.3607-3622.2003
Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348–60.
pubmed: 9362543
doi: 10.1007/s004120050256
Chaudhary N, Courvalin JC. Stepwise reassembly of the nuclear envelope at the end of mitosis. J Cell Biol. 1993;122:295–306.
pubmed: 8391536
doi: 10.1083/jcb.122.2.295
Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 2016;22:1488–95.
pubmed: 27841873
pmcid: 5359771
doi: 10.1038/nm.4210
Gollner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2016;23:69–78.
pubmed: 27941792
pmcid: 6548550
doi: 10.1038/nm.4247
Speroni J, Federico MB, Mansilla SF, Soria G, Gottifredi V. Kinase-independent function of checkpoint kinase 1 (Chk1) in the replication of damaged DNA. Proc Natl Acad Sci USA. 2012;109:7344–9.
pubmed: 22529391
doi: 10.1073/pnas.1116345109
pmcid: 3358916
Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee YJ, et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ. 2011;18:1771–9.
pubmed: 21546904
pmcid: 3190113
doi: 10.1038/cdd.2011.48
Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, et al. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. Cancer Cell. 2015;28:557–68.
pubmed: 26602815
pmcid: 4643307
doi: 10.1016/j.ccell.2015.09.015
Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, et al. RNAi screening of the kinome with cytarabine in leukemias. Blood. 2012;119:2863–72.
pubmed: 22267604
doi: 10.1182/blood-2011-07-367557
pmcid: 8221104
Caldwell JT, Edwards H, Buck SA, Ge Y, Taub JW. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer. 2014;61:1767–73.
pubmed: 24962331
pmcid: 4199830
doi: 10.1002/pbc.25081
Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter CC. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget. 2015;6:28001–10.
pubmed: 26334102
pmcid: 4695040
doi: 10.18632/oncotarget.4830
Garcia TB, Fosmire SP, Porter CC. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res. 2018;64:30–3.
pubmed: 29175378
doi: 10.1016/j.leukres.2017.11.004
Tamura K. Development of cell-cycle checkpoint therapy for solid tumors. Jpn J Clin Oncol. 2015;45:1097–102.
pubmed: 26486823
Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34:4354–61.
pubmed: 27998224
doi: 10.1200/JCO.2016.67.5942
Mendez E, Rodriguez CP, Kao MC, Raju S, Diab A, Harbison RA, et al. A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in head and neck squamous cell carcinoma. Clin Cancer Res. 2018;24:2740–8.
pubmed: 29535125
pmcid: 6004241
doi: 10.1158/1078-0432.CCR-17-3796
Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol. 2016;34:4371–80.
pubmed: 27601554
doi: 10.1200/JCO.2016.67.5991
pmcid: 7845944
Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, et al. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013;12:2675–84.
pubmed: 24121103
pmcid: 3897395
doi: 10.1158/1535-7163.MCT-13-0424
Li J, Duns G, Westers H, Sijmons R, van den Berg A, Kok K. SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget. 2016;7:50719–34.
pubmed: 27191891
pmcid: 5226616
doi: 10.18632/oncotarget.9368